CFM
OPTN

Catalyst Funds Management’s OptiNose OPTN Stock Holding History

Catalyst Funds Management’s Portfolio OPTN Stock Details OPTN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-480
Closed -$4.82K – 974
2024
Q3 		$4.82K Hold
480
– – ﹤0.01% 1241
2024
Q2 		$7.49K Buy
+480
New +$8.04K ﹤0.01% 982

Other funds holding OPTN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
MP
MVM Partners Boston, Massachusetts $10.8M AUM 61.97% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Catalyst Funds Management's OPTN Position: Q4 2024 in Review

Catalyst Funds Management sold out of OptiNose (OPTN) in Q4 2024, closing a stake of 480 shares — an estimated $4.82K sold.

Catalyst Funds Management first reported a position in OPTN in Q2 2024 and held it in 2 quarters. The position peaked at $7.49K in Q2 2024. 40 funds tracked by Wall St. Rank hold OPTN as of Q4 2024.

  • Catalyst Funds Management reported no remaining OptiNose position as of Q4 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 480 OptiNose shares in Q4 2024, an estimated $4.82K.
  • Catalyst Funds Management first reported a position in OptiNose in Q2 2024 and held it in 2 quarters.
  • Catalyst Funds Management's OptiNose position peaked at $7.49K in Q2 2024.
  • 40 funds tracked by Wall St. Rank held OptiNose as of Q4 2024.

Based on Catalyst Funds Management's 13F filing for Q4 2024, filed 10 Feb 2025.